RxDoctor Payments Data

Gregory Zaharchuk, MD

Diagnostic Neuroimaging · Stanford, CANPI 1376653675

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,683 of the $10,083 with a category attached, or 76.2%. Biogen accounts for 74.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $5,375 and has fallen 97.4% since, to $141 in 2024.

$10,083in general payments, 2019–2025

Across 12 payments — averaging $840.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$8K
  • GE HealthCare$2K
  • Fujifilm Healthcare Americas Corporation$172
  • Hyperfine Operations, Inc.$102
  • Siemens Medical Solutions USA, Inc.$39
$125,311in research payments, 2019–2025

Across 3 payments — averaging $41,770 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$119K
  • GE HealthCare$6K

What the payments were for

  • Consulting fees$7,68376%
  • Speaking & faculty fees$1,46715%
  • Travel & lodging$991%
  • Food & beverage$8348%

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,083 in reported general payments places this provider in the 80th percentile of 26 diagnostic neuroimaging providers in California.

See all diagnostic neuroimaging providers in California

Medicare billing

Part B allowed, 2024
$93,196
Medicare patients
766
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other diagnostic neuroimaging in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →